Wednesday, February 5, 2020

Xencor Licenses Antibody For Food Allergy Treatment

Monrovia-based Xencor says it has licensed the rights to its XmAB7195 monoclonal antibody, to Aimmune Therapeutics, a company that it working on treatments of food allergies. Xencor said it sold the rights to its antibody for $5 million in cash and $5 million in equity. Xencor also said the deal is worth up to another $385M based on clinical development, regulatory, and commercialization milestones. The company said it granted an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody to Aimmune. The XmAb7195 compound was originally developed by Xencor for the treatment of allergic asthma.